Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay off.' A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up.
對於一些投機商來說,投資一家可以扭轉命運的公司是非常具有吸引力的,因此即使是沒有營收、沒有盈利和一再受挫的公司,也能夠找到投資者。但正如彼得·林奇在《華爾街上的勝者》中所說的,『冤大頭幾乎從來不會得到回報。』一個虧損的公司尚未通過盈利證明自己,最終外部資本的流入可能會乾涸。
If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Amphastar Pharmaceuticals (NASDAQ:AMPH). Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide Amphastar Pharmaceuticals with the means to add long-term value to shareholders.
如果這種公司不符合您的品味,而您喜歡那些能夠產生營業收入甚至盈利的公司,那麼您可能會對amphastar pharmaceuticals (NASDAQ:AMPH)感興趣。即使市場認爲這家公司的估值相當合理,投資者也會認同,持續產生穩定利潤將繼續爲amphastar pharmaceuticals提供增加股東價值的手段。
Amphastar Pharmaceuticals' Improving Profits
amphastar pharmaceuticals的盈利不斷提升
In the last three years Amphastar Pharmaceuticals' earnings per share took off; so much so that it's a bit disingenuous to use these figures to try and deduce long term estimates. As a result, we'll zoom in on growth over the last year, instead. Amphastar Pharmaceuticals' EPS has risen over the last 12 months, growing from US$2.80 to US$3.26. This amounts to a 17% gain; a figure that shareholders will be pleased to see.
在過去的三年裏,amphastar pharmaceuticals的每股收益飆升;這些數據實際上有點不太誠實,用這些數據來推斷長期的估值。 因此,我們將把目光聚焦在過去一年的增長上。 在過去12個月裏,amphastar pharmaceuticals的每股收益已經增長,從2.80美元增長到3.26美元。 這相當於17%的增長;股東們會很高興看到這個數字。
Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. Not all of Amphastar Pharmaceuticals' revenue this year is revenue from operations, so keep in mind the revenue and margin numbers used in this article might not be the best representation of the underlying business. Amphastar Pharmaceuticals maintained stable EBIT margins over the last year, all while growing revenue 20% to US$724m. That's encouraging news for the company!
仔細考慮營收增長和利息稅前利潤(EBIT)率可以幫助了解最近盈利增長的可持續性。 amphastar pharmaceuticals今年的部分營收並非來源於業務運營,因此請牢記本文中使用的營收和利潤率數據可能並非最好地反映基礎業務。 在過去一年裏,amphastar pharmaceuticals保持着穩定的EBIt利潤率,同時將營收增長了20%,達到72400萬美元。 這對該公司來說是令人鼓舞的消息!
The chart below shows how the company's bottom and top lines have progressed over time. To see the actual numbers, click on the chart.
下面的圖表顯示了公司的營業收入和收益是如何隨時間變化的。要查看實際數字,請單擊圖表。
You don't drive with your eyes on the rear-view mirror, so you might be more interested in this free report showing analyst forecasts for Amphastar Pharmaceuticals' future profits.
您不會開車盯着後視鏡,所以您可能更感興趣,查看這份免費報告,顯示分析師對amphastar pharmaceuticals未來利潤的預測。
Are Amphastar Pharmaceuticals Insiders Aligned With All Shareholders?
amphastar pharmaceuticals內部人與所有股東保持一致嗎?
It's pleasing to see company leaders with putting their money on the line, so to speak, because it increases alignment of incentives between the people running the business, and its true owners. Shareholders will be pleased by the fact that insiders own Amphastar Pharmaceuticals shares worth a considerable sum. We note that their impressive stake in the company is worth US$191m. Holders should find this level of insider commitment quite encouraging, since it would ensure that the leaders of the company would also experience their success, or failure, with the stock.
看到公司領導人把他們的錢投入到公司中,這讓人感到高興,因爲這增加了公司管理人員和真正業主之間的激勵一致性。股東會對內部人擁有數量可觀的amphastar pharmaceuticals股票感到滿意。我們注意到他們在該公司的令人印象深刻的股份價值1億9100萬美元。持有人應該會發現這種內部人承諾水平相當令人鼓舞,因爲這將確保公司領導人也將與股票的成功或失敗同在。
Is Amphastar Pharmaceuticals Worth Keeping An Eye On?
amphastar pharmaceuticals值得關注嗎?
One positive for Amphastar Pharmaceuticals is that it is growing EPS. That's nice to see. To add an extra spark to the fire, significant insider ownership in the company is another highlight. These two factors are a huge highlight for the company which should be a strong contender your watchlists. Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Amphastar Pharmaceuticals that you should be aware of.
amphastar pharmaceuticals一個積極因素是其EPS的增長。這是一個令人高興的現象。再加上公司內部人員對公司的重要持股,這也是另一個亮點。這兩個因素是公司的重要亮點,應該成爲您觀察清單的強大競爭者。不要忘記仍然可能存在風險。例如,我們已經發現amphastar pharmaceuticals存在1個警告信號,您應該注意。
Although Amphastar Pharmaceuticals certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see companies with more skin in the game, then check out this handpicked selection of companies that not only boast of strong growth but have strong insider backing.
雖然amphastar pharmaceuticals看起來不錯,如果內部人員正在大量買入股票,可能會吸引更多投資者的興趣。如果您喜歡看到更多內部人員參與的公司,那麼請查看這些精心挑選的公司,它們不僅擁有強勁的增長,而且有強大的內部支持。
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
請注意,本文討論的內部交易是指在相關司法管轄區中報告的交易。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。
譯文內容由第三人軟體翻譯。